Data Provided by Refinitiv. Minimum 15 minutes delayed.
Corporate Profile
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Events
-
May 5, 2022 at 6:00 PM EDT
-
Apr 13, 2022 at 8:00 AM EDT
-
Mar 16, 2022 at 12:40 PM EDT
Press Releases
-
Aug 08, 2022
-
Jul 27, 2022
-
Jun 24, 2022